| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 30.9 | 27.1 |
| Gross profit | 14.0 | 11.8 |
| Profit before tax | -11.8 | -13.3 |
| Net income | -13.1 | -13.7 |
| EPS (diluted, $ a share) | $-0.19 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +14.1% |
|---|---|
| Gross margin | 45.2% |
| Operating margin | -41.9% |
10-Q filed with the SEC, NASDAQ: OSUR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Orasure Technologies Inc: key numbers
- Share price
- $3.60Close, Nov 16
- Market cap
- $249M
- Shares outstanding
- 69.05MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Orasure Technologies Inc
All →Orasure Technologies Financial Results
OraSure Technologies reported Q3 2026 financial results with 14% year-over-year revenue growth to $30.9 million, driven by its core business strategy. The company saw GAAP gross margin expansion to 45.2% and received initial orders for its newly launched Colli-Pee Dx and OraQuick Ebola 2.0 products.
- Term
- Q3 2026
“Our third quarter results demonstrate the continued execution of our strategy. In addition to delivering double-digit year-over-year revenue growth, we meaningfully expanded gross margins and benefited from operational efficiency initiatives that reduced our cost base.”
Carrie Eglinton Manner, President and CEO
“Looking ahead to the fourth quarter and into 2027, we believe we are well positioned for continued revenue growth. Supported by a robust balance sheet, we will continue to invest behind initiatives to accelerate topline growth, improve our operating model, and drive towards profitability.”
Carrie Eglinton Manner, President and CEO